Good morning, everyone, and welcome to the 2026 Annual General Meeting for PYC Therapeutics Limited. My name is Steve Ledger, and I am one of the Company Secretaries of the company. Before we begin, a few housekeeping matters that I will just cover off on. There are emergency exits on the left and right sides of the stage and an exit door at the top of the auditorium. All exits are clearly marked with green exit signs. If an alarm sounds, please leave calmly via the nearest exit and follow the directions of the building wardens. First aid is available at the concierge desk, and the nearest toilets are in the main foyer. I would also like to acknowledge the Whadjuk people of the Noongar Nation, the traditional custodians of the land on which we meet today, and pay my respects to elders past and present.
I extend that respect to Aboriginal and Torres Strait Islanders peoples here today. I will briefly outline the proceedings and practical arrangement for today's meeting before inviting the Chair, Peter Coleman, to take the chair. The formal business will include consideration of the company's financial reports and the resolutions set out in the notice of meeting. Shareholders will have an opportunity to ask questions relevant to each resolution before it is put, and the general questions after the CEO's update. Voting on all resolutions will be by poll using the Automic voting cards provided to you when you registered and came in. Each Automic voting card lists all the resolutions. Please mark your voting preference for each resolution as it is considered and retain your card until it is collected at the conclusion of the resolutions.
Cards will then be counted and reconciled with the proxy votes before the results are announced. I will now invite the Chair of PYC Therapeutics, Mr. Peter Coleman, to take the chair.
Good morning, everyone. I can welcome. What a year we have had. Firstly, I can assure you that blue is now not the formal color of the company. I noticed we are all in blue this morning, so, Rohan, I am not sure if that memo got out to us at all. Firstly, look, thanks for your support. It has really been a heck of a year, to be quite honest with you. I will open the meeting. I will confirm a quorum is present and that the meeting is properly constituted. I therefore declare the meeting open. This is a very formal meeting, so bear with us, please, as we go through a number of items on the agenda that are things that we must do under the Corporations Act.
I'll give a summary of where the board has looked this year and what our priorities have been as we look into 2027, and I'm sure you're very interested to hear what Rohan has to say about the programs we have. We'll give Rohan some time at the end. We'll have plenty of questions, and then we'll wrap it up. Before we kick off, for those who don't know us, I'd like to introduce my fellow directors. Of course, Professor Ian Constable AO, and Dr. Rohan Hockings, our Chief Executive Officer. We also have Steve Ledger, who you've just met, and Jonathan Riley sitting next to Steve. They are our Joint Company Secretaries. Of course, Adam Thompson is representing our external auditor. Adam's down the end there. He's also in attendance.
The AGM's an important opportunity for shareholders to consider the company's performance, hear about its progress and priorities, and ask questions of the board and management. Of course, the format for today's meeting will be as follows. Firstly, I'll provide an overview of the board's priorities and its perspective on PYC's project progress, and then, as I mentioned, our priorities as we focus on the year ahead. Next, I'll consider the company's financial statements and attend to the formal business of the meeting, which, on conclusion, will be followed by a presentation from Rohan, as I mentioned. I'll then announce the results of the meeting after the CEO update. So firstly, what's the board been doing?
You might recall, for those of you in the room, and I think I probably speak for all of you, we were here this time last year, and we were just starting to form the board. Owen was stepping down as Chair. Ian was on the board and had just was coming onto the board directly after the meeting. It's been a very fruitful year, I think, and I really want to thank both you as shareholders for your support during the year. We've had a number of things that we've put to you, including an Extraordinary General Meeting. But most importantly, the management team, led by Rohan, and you've seen some tremendous progress through the year, and you'll hear about what 2027 has in front of us. But also very importantly, to welcome some new members of the management team.
So you'll find there's some new people in the room if you haven't met them before. Thomas, put your hand up, please. Thomas has joined us as our CFO during the year. Of course, you've just met Jonathan and Steve. They're part of our build-out of the team. Of course, we're also building out our clinical team, both here and in the U.S. as well. So we've been very active in the human capital part of the business and being able to build the organization up so that we can support Rohan to really focus on the things that only the CEO can focus on. I must say, as a board, standing here today, I'm pleased with the progress we've made in that area, and I'm very pleased with the new team members that we have brought on board.
Now, we haven't finished, and that recruiting process will continue, but it's matching the programs that we have in place as we need to build out the organization to be able to execute on the four programs that we have in play. Last year, when Ian and I got together after the AGM, we had four clear objectives. One was to contemporize governance to reflect PYC's maturity, and very importantly, to prepare it for its future growth, and of course, broadening our shareholder base. I think we've done very well in that regard. Of course, we took the opportunity during the capital raise to broaden the shareholder base. New shareholders have joined us, of course, as we've joined the S&P/ASX 300.
But very importantly, behind the scenes, we've done a lot of work in contemporizing the board with respect to our ASX requirements, listing requirements, to make sure that we were ready for joining the S&P/ASX 300. For those of you who are not familiar, there are different requirements as you grow as a company, minimum requirements when you're a startup, but as you become more mature as a company, there are other governance requirements that you're required to put in place. That includes also formalizing some of the committees for the board. For those of you who watch our website, you would have seen that we've just posted the charters for three new committees.
But behind the scenes, we've also done a lot of work on policies and procedures, and the sorts of things that you would expect companies to go back and reflect on from time to time, and that was an opportunity for us over the past year to do that and make sure that we were ready, and the things that we needed, that supporting platform, that foundation that we need as a company were in place. Because as we know, governance is not an option. Governance is our right to play, and making sure that we have the right governance processes in place, the right people to execute on those is extraordinarily important, because we don't get to play if we don't get those right.
Importantly, of course, it provides then a solid platform for Rohan to be able to move on with the clinical team in moving forward in creating that shareholder value that we all know this company has. The second thing we did was really realigning our key objectives. As you know, there was a debate over what the strategy should be, whether we should be pursuing a single program or whether we should be pursuing all four programs. The board sat with Rohan, and we reviewed that, and we made the decision, obviously, to pursue all four programs. We thought there was value in all four programs. We also thought there was value in PYC carrying forward those four programs. That's distinct from going into an M&A process and trying to monetize some of those programs early and fund others and so forth.
That was really just having a view that we thought all four programs had merit. They all deserved the capital allocations that they required, and that the best value was in the hands of PYC, and that is how we could create that. So, that was the view that we formed. Of course, with that, then we needed capital. The third objective then was to recapitalize the company. This was a judgment call for us and a long debate, as you can imagine. We had gone through a period of time where you could say we were capital light, which was appropriate given where the programs were. Capital light meaning we did not want to dilute shareholders' equity and so forth. We just had a line of sight to the next milestone.
The capital raises that we had really gave us a line of sight to the next milestone, and then we stopped, and we paused, and we said, "Okay, now do we want to go to the next one?" and so forth and so on. That is a very appropriate way of managing capital in the early stages of a company as you start to de-risk those programs. We felt, though, we were at a point where, particularly the PKD program itself was fast becoming de-risked, and there was an opportunity for us to bring on new investors, broaden that investor base. We went hard on the capital raise. Now, there are a couple of things for that. Of course, it was very well supported. It allowed us to bring on a broader investor base.
Very importantly, and of course, these are soft things that you do not see in the numbers, it has allowed us to recruit the very best people. It gave our clinical teams the certainty that they need to be able to keep their teams together, to be able to get the people on board that I have just mentioned today, because they can see a runway now out to 2030. They can see that they have a shareholder base that is committed, and they can see that they have got a board that is committed. They are not just simply waiting here now for the next raise, and we are not come raise anymore. So, that is gone, which is a really important part about it, because I think we now chart our own journey as a company, and I want to thank you for your support during that process.
It was extremely important for us to get that away and to get it away as well. The third item was, of course, to work with Rohan and the team to make sure that we flawlessly executed on the promises that we had made. I must say, I would give us an A on that this year. There is always slippage here and there in programs, but the team has done a really nice job at being able to catch up on things that have slipped, put other things in their place, and so forth. So, you are starting to see maturity now in the programs whereby we can flex within the organization and move forward, and we have got enough depth now and competence, and I would say confidence in the organization that we are able to execute on those programs. We are on a journey as a company.
Let us be clear. We haven't been here before. This is a journey. We, as a company, have not been here before. We have not demonstrated we can take things through phase III before, and we've had that conversation. It's, you know, what are we, and what is the culture we're developing, and how do we make sure we execute, and how do we make sure that we deliver on the promises and really are able to achieve the outcomes that we all desire? I think that's really important for us to acknowledge that our teams also are growing and learning as we go. I think once you have that conversation, then you can have other conversations where you can put your hand up and say, "I need help," or, "I'm uncertain about something," or, "I need additional support in this area," and so forth.
I can assure you, as an organization, we are maturing in that regard, and we're understanding that. Now, doesn't mean that Rohan has backed off on the accelerator at all, and so forth and so on. It just means that we're having good conversations, and more importantly, we're having early conversations. Then importantly behind that, we now have the depth in the organization and the breadth in the organization of competency in people to be able to react and to be able to flex in what we're doing. What we're doing is not easy, as many of you in the room know, and there are some things here that are critical success points for us moving forward. Not the least of which, you know, we often talk about the outcomes of the programs.
One of the big success points, though, is the inputs of the programs, and particularly getting patients into our programs and be able to get that pipeline moving through, and extraordinarily important. This is where many companies in this area actually fail to deliver, is fail through that clinical phase, is getting the patients actually in the door, not just the outcomes. It's being able to do that. So that's the company we are today, and we'll continue to build that. Now, as Rohan will talk about, the future is we have to keep doing that. Simply, the pace that we're running at today is not going to deliver gold for us. So we're still going to have to up the pace, but that's what we're all about, and that's, I can tell you, Ian and I are working closely with Rohan and the team on that.
I've talked about the programs being adequately funded. So if you think about it, then the four things that we said we would do is contemporize, that we would also align the key objectives to the four programs, we'll work with management to ensure flawless execution, and then we talked about adequately funding the program. So if you think about that for the four objectives for the year, that's a pretty big list for a pretty small team, and so forth. Underpinning that, as I mentioned, you know, there are other things that we don't talk about. Suddenly, we had to develop a treasury function. Didn't have one because we didn't have money that we needed to manage. Now we've got a proper treasury function and process in place. It's being managed by treasury professionals and so forth and so on.
So you can be assured that the money that you have given us to execute on these programs is being properly managed and looked after. These seem trivial things, and you think it should just happen. I can assure you, going through a risk matrix and trying to understand what sort of risks that you want and what sort of returns are appropriate, what currencies you want to hold it in, how much, when, and so forth and so on, is far more complex than you would expect. Coming into 2027, of kind of cutting through the list, 2027 really is focusing on two areas. I'm talking 2027 financial year. Two areas. One is simply supporting management to execute the programs that we have in place. You know, the board is really about that and doing that.
Then, of course, the second one is making sure that we build out the board competence ourselves. We've talked about building up a leadership team. Ian and I have been working with an external search firm to identify two additional board members to bring on. We've identified people through the year. We've had some interviews. Unfortunately, we weren't able to get those people on. We've now gone out to Russell Reynolds. You might be familiar with them. They're a tier 1 executive search firm. We've engaged them, and we're in the process of going through what they call a long list of candidates. Then, of course, we get down to a shortlist, and then we start interviewing people. So you should see something in Q1 of next year with respect to building out the board. There are two key skill areas that we're looking for.
The first one of those is obviously getting somebody in the U.S. who has experience running through, you know, phase II, phase III in clinical trials, getting through the FDA process, and so forth and so on, and somebody who's senior in their leadership or has been senior in their leadership roles. As you can imagine, that is a hotly contested individual with where biotech is at the moment. So we've got to put our best face on, so to speak, and we've got to be able to convince somebody that what we're doing is truly unique and life-changing. I'm confident we can do that once we identify the right people, but I can tell you it's not going to be easy. That's not because of the things that we're doing are not worthy of it.
It's just simply it's a highly competitive market, particularly for U.S. directors with that particular skill set. I think that's just the reality of where we are. We're also setting the bar high, so we're not just simply looking for somebody who happens to be in biotech in the U.S. That wouldn't serve us well. We want somebody who really can bring value and bring insights and help Rohan and the team and the board kind of move through that process. The second person we're looking for is somebody really with finance skills, particularly ECM or M&A skills, and also be able to help Thomas and the team as we move towards a potential NASDAQ listing next year. I keep saying potential. I know we've made commitments, but it's always potential until we actually say yes.
We will keep it as potential, but I can assure you the board is committed to working with Rohan and the team in moving to a U.S. listing next year. I must say the New York Stock Exchange is hotly contesting this at the moment with NASDAQ, so a little bit of competition doesn't hurt for us. We will make a decision under advice as to where we think the best listing would be, and also the structure of that listing. Some of you might be thinking, "Well, what does that mean as an Aussie shareholder and so forth? Am I able to trade my shares and so forth?" Absolutely, you will. Australian listing rules allow you to do that, meaning you can hold Australian shares, and that's where we will be. We have had lots of conversations. I remind everybody, it's our Australian shareholders that drive our share price.
It's our Australian shareholders that have been supportive of us through this journey. It's our Australian shareholders that deserve to be part of this journey and to come along with us. We will keep that. We will make sure that's a part of whatever structure that we put in place, and then we will consider as a board how long we think it's appropriate to keep that structure in place, and we will give you an indication for that as we bring it to you. There will be some administrative things around that we will need to bring to you, and we will have decisions that you think, "Well, why bother?" But we have to bring it to you under the Corps Act. One of those might even be the name of the company, and so forth.
There's just a big long list of things that we're doing, but we will be working with our auditors to work our way through that. In fact, we have a representative from our auditors now who's an expert in U.S. capital markets, as part of that as we go through that. So that's 2027. Only two things, but there's a lot in that, as we go through that. With that's really the end of my detailed remarks. What I'm going to do now is go into the body of the board meeting. Before I move into the more formal part, any questions on what I have said this morning? I hope you get a sense we're working hard, and we are focused, and we are very grateful to have the opportunity to work with such a great company, to be honest with you.
All right, let's move on then. The next item of business is to receive and consider the company's financial statements for the year ended 30 June 2026, together with the director's report and auditor's report as set out in the annual report. I apologize, guys, in advance, I'm going to be reading a lot because these are very formal things that we need to do. So, you will be testing my reading skills. No resolution is required for this particular item, but I do invite questions or comments on the accounts, the financial reports, and the management of the company. The company's auditors, PricewaterhouseCoopers, are represented here today by Adam Thompson. Adam's sitting down the end of the table there, in accordance with the requirements of the Corporations Act.
Now, Mr. Thompson's available to answer questions concerning the conduct of the audit, the preparation and content of the auditor's report, the accounting policies adopted by the company, and the auditor's independence. Mr. Thompson will also be given an opportunity to answer any written questions submitted under Section 250PA of the Corporations Act. Now, are there any questions for Adam? We rarely get any questions on this, Adam, I'm sorry. But I can assure you, it's been a joy to work with Adam and the team over the last 12 months, and I'm sure Adam's helped Thomas with his onboarding as well. So thank you very much, PwC. We'll now get into really the formal business of the meeting. Now, the company's received 462,737,534 valid proxy votes from 109 shareholders, representing approximately 46.99% of the company's issued capital.
Don't you like the fact we say approximately and then we go into two decimal places? A summary of the voting for each of the resolutions is displayed and is available for inspection. You can run through the numbers there, and Steve is the expert on this, so any questions to Steve. As stated in the notice of meeting, I intend to exercise all available proxies in favor of each resolution unless the shareholder has expressly indicated a different voting intention. Now, this is subject to the voting exclusions and prohibitions that apply to each of the resolutions. And of course, I'm prohibited on voting on a couple of those, as is Ian.
Where I've been appointed as a proxy and no voting direction has been given, the notice of meeting expressly authorizes me to exercise the proxy in respect of the resolutions that are connected directly or indirectly with the remuneration of the company's key management personnel. Now, after each resolution is displayed on the screen, I will invite questions from the floor. I'll be limiting questions to the resolutions being considered, so if you can, just hold your questions, and we'll get to them in the order. It just helps us in running the meeting. But we'll also give you a chance at the end if you think of something that we can do a bit of catch-up as we wrap up at the end. Now, shareholders will also be provided an opportunity to ask questions on the resolutions that I mentioned.
Just please state your name for the record when you address the meeting so the guys can just make sure we keep a record of the questions and make sure we address them appropriately. Now, I have to say this, I don't expect this from this group, but if a question is asked, in my opinion, which does not relate to the resolution before the meeting, I will rule it inadmissible. It's unfortunate, but that just happens sometimes in AGMs. In my capacity as chair, all resolutions today will be decided by a poll rather than a vote on a show of hands. Accordingly, the resolutions will be for discussion purposes only. Now, the poll will be taken once we've been through all the resolutions. Ballot papers were given to eligible shareholders at the time of registration and will be collected following the resolutions.
Now, results of the poll will be announced to the market later today and following the CEO presentation. So before we wrap up today, Steve will give us the results of the poll, and then we'll post them obviously to the ASX. Please note that each shareholder can only vote for their personal shareholding at this time. Only proxies validly lodged with the company up to 48 hours beforehand will be counted in the vote. Resolution number one is adoption of the remuneration report. We now turn to resolution one, the remuneration report. The proxy votes are shown on the screen. Yes, they're up there, which is great. The notice of meeting describes this as an ordinary resolution. Votes on this resolution are advisory only and do not bind the directors of the company, although I will admit we take a lot of notice of it.
Whilst it's not binding, it's an advisory vote, it's one that we take very seriously. Now, I'll invite any questions or comments from shareholders. Nothing? Steve, was there anything sent in? Okay. If there are no further questions, I'll formally put the following ordinary resolution, that the remuneration report for the year ended 30 June 2026 be adopted by the companies. Please mark your voting preferences for this resolution on your Automic voting card. Please retain the card. All cards will be collected after the resolutions have been considered. Now, resolution number two is in relation to myself, so what we'll do here is I'll just hand over to Steve, who will run the meeting for this resolution. Steve.
Thank you, Peter. We now turn to resolution two, the re-election of Mr. Peter Coleman as a director. The proxy votes are shown on screen. Perfect. The resolution is set out in the notice of meeting and explanatory memorandum. I invite any questions from shareholders. Thank you. I'll formally put the following ordinary resolution, that Mr. Peter Coleman, who retires in accordance with rule 20.3 of the constitution of the company and Listing Rule 14.4, and being eligible, offers himself for re-election, be re-elected as a director. If you could please mark your voting preference for this resolution on your voting card now. I'll now return the chair to Peter. Thank you.
Thanks, Steve, and thanks everybody for your support. Just one thing to note as we go through this year and we look at re-election of directors and so forth and so on. One thing my fellow directors, Ian and I, have decided is that, again, moving to a more contemporary, more open process with respect to election of directors, we will be moving to a one-year re-election cycle on this, as distinct from the three-year that you see with a lot of Australian companies. One, this is to align with where the U.S. is. Most U.S. companies have directors re-elected each year. Also, I think it reflects kind of where PYC is in our journey, but more importantly, directors need to be accountable. And in my view, a one-year re-election is fine. If we're not doing our job, it gives you an opportunity to tell us that.
If we are doing our job, we thank you very much and we will continue to serve. There are a few things in there that we as Directors are moving. You will also see on the remuneration some changes as well. Resolution three is re-election of Professor Ian Constable AO as Director. We now turn to that resolution. The proxy votes are shown on the screen, and the resolution itself is set out in the notice of meeting. Now I invite any questions or comments from shareholders on this resolution. Right. If there are no further questions, I will formally put the following ordinary resolution, that Professor Ian Constable AO, who retires by rotation in accordance with rule 20.6 of the constitution and Listing Rule 14.4, and being eligible, offers himself for re-election, be re-elected as a Director. Please mark your voting cards, if you wish, for this resolution.
I must say, I have been very honored to be able to work with Ian over this past year. I think we have developed a wonderful and respectful relationship and working with Rohan and the team. I couldn't have asked for a more supportive Director coming into PYC. So, Ian, thank you very much for your support. We now turn to resolution four, approval of the issue of options to Dr. Rohan Hockings. The proxy votes are shown on the screen. The resolution is set out in the notice of meeting and the explanatory memorandum. I invite any questions from shareholders on this resolution. Okay. So no questions.
I will formally put the following ordinary resolution, that for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the company to issue up to 1,500,000 options to the Executive Director and Chief Executive Officer, Dr. Rohan Hockings, or his nominees under the PYC Therapeutics Limited Rights Plan on the terms and conditions described in the explanatory memorandum. Now, please mark your voting preferences for this resolutions on your Automic voting card if you have not voted previously. Moving on, resolution five is approval to issue restricted rights to Dr. Hockings. The proxy votes are shown on the screen. Resolution is set out in the notice of meeting and explanatory memorandum. Are there any questions from shareholders on this resolution? So no questions.
I will formally put the following ordinary resolution, that for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the company to issue up to 289,855 restricted rights to the Executive Director and Chief Executive Officer, Dr. Rohan Hockings, or his nominees under the PYC Therapeutics Limited Rights Plan on the terms and conditions described in the explanatory memorandum. Now, please mark your voting preferences for this resolution if you have not done so on your Automic voting card. We now turn to resolution six, approval to issue performance rights to Dr. Rohan Hockings. The proxy votes are shown on the screen. The resolution is set out in the notice of meeting and explanatory memorandum. I now invite any questions or comments from shareholders. So no further questions.
I formally put the following ordinary resolution, that for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the company to issue up to 810,381 performance rights. I better put my glasses on to make sure I read the right number out here, Rohan. Performance rights, the Executive Director and Chief Executive Officer, Dr. Rohan Hockings, or his nominees under the PYC Therapeutics Limited Rights Plan on the terms and conditions described in the explanatory memorandum. Please mark your voting preference for this resolution on your Automic voting card if you've not done so already. We now turn to resolution seven, approval to issue options to Professor Ian Constable. The proxy votes are shown on the screen. The resolution is set out in the notice of meeting and the explanatory memorandum. Are there any questions from shareholders on this resolution? Yes. Yes, Steve.
Against this resolution and also the one issuing options to Rohan.
Yeah, Steve, really good question. Life's all a matter of timing sometimes. These, to be quite frank with you, particularly with respect to Ian, these options we would have preferred to have done at this time last year. That's really when these came about. It was part of really Ian signing on, but by the time the notice of meeting went out last year, the notice of meeting went out before the board at the time, I wasn't on the board, but before they realized that remuneration needed to be dealt with. Ian did the right thing, just simply came onto the board and said, "I'll help out." Obviously, as the board had discussions with me, they realized that it was appropriate to issue options given that the existing board members had options.
Ian had not been offered any options at the time. So the notice of meeting had gone out, and so at that point, of course, the board couldn't issue options to Ian as part of his coming onto the board. So it should have been dealt with then. Unfortunately, it wasn't because of the timing and everything else that was happening. For myself, it was different because I simply negotiated that as part of my contract coming into the board, and so the way the Listing Rules work, because that was in my contract, then that did not need to go to shareholders. So it was just a different set of process. So it should have been dealt with then. It wasn't, unfortunately. We had another option to catch it at the EGM, and we were provided external advice that we did not need to put it to shareholders.
Unfortunately, between receiving that advice, sending out the notice, we looked at it a lot harder and determined, in fact, we needed to take it to shareholders. So again, if you think about timing, it should have been dealt with then. The votes against are principally through the proxies. So as we listed, sorry, as our listing changed and we went into the S&P/ASX 300, we've got a lot of passive funds that have come in, particularly superannuation funds and so forth, they've come in. And of course, they came on board in September of this year. So they're looking at something now and saying, "Issuing options to a director doesn't fit within our guidelines." I've met with all of the proxies and explained the history and so forth. They're very understanding of it.
But for them, they just said, "It just doesn't fit within our guidelines, so we're going to recommend against it." There was no angst in that at all. It was just simply, they understood we're on a transition as a company. It's quite normal to issue options early in your life, but of course, as you grow and you start to move up the ASX into the different indexes, whether it's the 300 or the 200, then there's different expectations. The company's bigger, and you should be able to remunerate directors differently and so forth. That's why you're seeing now. So it was just, most of it was really around the proxies, but equally, we just had some new shareholders coming in. Now, it's obviously roughly 25% of our register by capital now is U.S. investors. They have a different view of that, of course.
They like directors to have skin in the game. There's always this thing around proxies and are they premium price, sorry, options, and are they premium-priced options or not? Clearly, these were all premium-priced options, which means that neither Ian, myself, or Rohan receive anything until certain returns have been met. Then, of course, it's not the accounting methodology that you'll see in the annual report, which is a lot different to the reality of the world, as you know, with respect to the valuation. With respect to the U.S. shareholders, they expect directors to have significant skin in the game. So you'll find that Ian and I also put in place a minimum holding for directors of equivalent to one year of our remuneration, not the cash component, but one year of the total rem.
You'll find in the U.S., they often talk about three years or more of that. They're a little selective because they only use the cash component of that. They don't use the total rem. Ian and I are using the total rem. U.S. directors also have the opportunity to defer their tax point on any shares that are received by up to 10 years. So, whereas in Australia, you're taxed when you receive them. So there are just different ways we work through that. We've agreed, so we've got a minimum of one year of remuneration as a holding. You'll find, you would have seen in the ASX announcements, the Appendix 3Ys that both Ian and I have been purchasing shares, as has Rohan. We're believers in the company, and we're supportive of that.
We've also put in place that Ian and I will receive 40% of our remuneration as equity rights. So to be clear, not performance rights. So Rohan receives performance rights. He receives them based on achieving certain performance hurdles. For Ian and myself, it's simply equity rights. That then again fits in with what proxy advisors are looking for. A lot of the larger shareholders, they don't want directors to have at-risk shares, so to speak. But it is at risk because we're putting it into the company, right? So it's, we're with you on this particular journey, but we thought 40% of our total remuneration purchased as equity, and we have a holding period on that. We can't trade them immediately, was appropriate, again, to demonstrate to you that we're putting our money back into the company. So again, a couple of changes there.
That is not the normal thing on large Australian companies, as you know. They typically like them to take it all as cash. I have had this conversation with the proxies. Again, they understand. We will have to answer that question every year, but I personally think it is very appropriate, and I will continue to push on that with your support. Clearly, if we get feedback from the broad shareholder group that it is not appropriate, then we will go back and review that. But at this point, the view of the board, my view is that it is very appropriate for where PYC is in our growth cycle. Did that answer that question? Yeah, it was really just the new shareholders that have come on the journey, but it was really driven by the proxies. Thanks for that question.
All right, if there are no further questions, I will formally put the following ordinary resolution that for the purposes of Listing Rule 10.11 and for other purposes, approval is given for the company to issue up to 1 million options to Non-Executive Director Professor Ian Constable AO or his nominees on the terms and conditions described in the explanatory memorandum. Now, please mark your voting preference for this resolution on your Automic voting card if you have not done so already. Okay, we now turn to resolution eight, approval to grant rights to Professor Ian Constable. Proxy votes are shown on the screen. The resolution is set out in the notice of meeting and the explanatory memorandum. I invite any questions or comments from shareholders. Maybe, to point out the obvious, you can see on the screen that the difference in the voting, on there.
In general, we have got strong support for what we have done with respect to changing the remuneration structure for the directors. I must say, Ian, I want to thank you for your support in increasing the director pool, during the AGM earlier this year as well. That allows us then to attract the right types of people that we need on here. Again, as I mentioned, this is a highly contested space, so we want to make sure that we get the right people coming through.
With that, if there are no questions on that, I will formally put the following ordinary resolution, that for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the company to issue up to 42,373 rights to Non-Executive Director Professor Ian Constable AO or his nominees under the PYC Therapeutics Limited Non-Executive Director Equity Plan on the terms and conditions described in the explanatory memorandum. Please mark your voting preferences for this resolution on your Automic voting card. As you can see from that implied, we also had to develop, obviously, a Non-Executive Director Equity Plan, along with the executive and employee equity plan. A lot of administration getting these in place during the year. I will now hand over the chair temporarily to Steve because the next item is about myself.
Thank you, Peter. We now turn to Resolution 9, approval to grant rights to Peter Coleman. The proxy votes are shown on screen. The resolution is set out in the notice of meeting and explanatory memorandum. I will now invite questions or comments. Thank you. I will formally put the following ordinary resolution, that for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the company to issue up to 61,441 rights to non-executive director Mr. Peter Coleman or his nominees under the NED plan on the terms and conditions described in the explanatory memorandum. If you could please mark your voting preference on the voting card now. I will now return the chair to Peter.
Thanks, Steve. Thanks everybody for your support. Resolution 10, this is really the renewal of the proportional takeover provisions. The proxy votes are shown on the screen. The notice of meeting describes this as a special resolution. I invite any questions or comments from shareholders. Okay. If there are no further questions, I will formally put the following special resolution, that for the purposes of Section 648G of the Corporations Act and for all other purposes, the existing proportional takeover provisions in the form set out in Rule 38 of the constitution be renewed for a period of three years commencing on the date of the meeting. Please mark your voting preferences for this resolution. Whilst it may seem general admin, this is a very important resolution, so thank you for your support.
Obviously, PYC is at an important inflection point in its growth, and this resolution makes sure that we have all of the means at our hands to be able to ensure that we protect our existing shareholders' rights. So thank you very much for that. Resolution 11 is ratification of prior issue of shares. This really goes back to February when we issued shares up to our 15% cap as part of the capital raise. This is just simply refreshing the cap. The cap will get naturally refreshed again in February of next year, just on the 12-month rolling requirement for that. But it is just making sure that as we go into the Christmas period, we do not receive something that we were not expecting and then we are not prepared to do it.
So we just need to make sure that we have got everything back in place at this point. Resolution 11 really is the ratification of a prior issues of shares. The notice of meeting describes this as an ordinary resolution. The proxy votes are shown on the screen. Resolution set out in the notice of meeting and explanatory memorandum. One thing you will note on the votes, there is quite a large number that actually were not able to vote. This is simply because they received those shares as part of the capital raise. So these are just simply shareholders that have voted that were unable to vote on this particular item because they received shares. So there is nothing untoward in that. You just then see that our larger shareholders participated in that raise.
So you can see the very disproportionate number there, just as our larger shareholders participated in that raise. They have had to stand out, so to speak, on this particular resolution. If there are no further questions, I will formally put the following resolution, that for the purposes of Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issue of 85,489,067 ordinary fully paid shares in the capital of the company issued on 11 February 2026 at an issue price of AUD 1.50 per share pursuant to the institutional placement announced by the company on 2 February 2026 on the terms and conditions described in the explanatory memorandum. Please mark your voting preferences for this resolution. I am sure you will be pleased to know voting on all resolution is now complete.
It is now time to take polls for the resolutions one to 11, and a representative from the Automic Share Registry will act as returning officer and will collect voting cards. I will just give you a couple of minutes to do that. I think we have got another card here. We collected all the cards. While we tally the votes, the main act of the day, we will hand over to Rohan. Rohan will give you an update on what is happening with the company and what we can expect in 2027, and then I will come back and just formally wrap up the meeting and close.
Thank you, Peter, and good morning to everyone. Before we begin, just a couple of administrative items. I want to remind you that today's presentation is being recorded, and also to make the following safe harbor statement. Reminding you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in our filings with the Australian Securities Exchange. As such, actual results may differ materially from what we discuss on today's call. We disclaim any obligation or intention to update these statements in the future. Before I begin, a big thank you to Peter and Professor Constable for your stewardship of the company throughout the course of the year.
I think, as you pointed out, Peter, a lot has been achieved over the course of the past 12 months, and I think in large part that is credit to the clarity and calmness that you and Professor Constable have brought to the boardroom. So, a big thank you to you both. In addition to some of the newer staff members who are joining us today, we also have some of the stalwarts from the longer journey that PYC has been on. Drug development is a difficult journey at the best of times, and when you are trying to do it outside of the U.S., it is even harder. There have been extraordinary efforts on the part of many of our staff members throughout the course of the year, and for that, I am very grateful.
So, a big thank you to those who have supported the execution of what has been realized at the company level. I would also like to thank the patients and families who volunteer for our clinical trials. It is a very brave decision indeed to volunteer to take an investigational drug candidate. So, a big thank you to all of those people who are willing participants in those studies, and also to the clinicians and the clinical research staff who support them. I am going to introduce the company before I frame the agenda for today, but in terms of the format, I am very happy to open up the presentation for discussion as we go through so that each of you have a chance to engage in the topics as we review each candidate in the pipeline from top to bottom. We have some microphones here.
Please do feel free if there is anything of interest throughout the course of the presentation to raise questions then. We will also open up for Q&A at the end, with the objective being really to give you as full and frank an assessment of the company's progress, where we are today, and what we see as likely to unfold over the course of the next 12, 24 months as possible. We will address each of the questions that you put to us. For those who are new to the story, PYC makes precision medicines for patients who have great unmet needs, and we do it in a very particular domain of the genetic medicine space.
We make drugs for patients who have a mutation in one copy of one gene only that is driving some kind of functional deficit in the cell, that is manifesting as the particular disease in question. An illustration of that, we see here Sierra, who has a syndrome called Phelan-McDermid syndrome. This is caused by a mutation in one copy of the SHANK3 gene. Sierra is expressing in her neurons or her brain cells half as much of that SHANK3 gene as she requires, and consequently, the neurons are not able to communicate with one another properly. We design a drug that does nothing with the mutated allele at all, but rather engages with the remaining good copy of the gene and enhances the translational process. It tells the one copy of RNA that does remain to make two units of protein.
In doing so, it compensates for that loss of function mutation and creates a quantitative cure for that condition. That is common throughout the entire pipeline of drug candidates that PYC is developing. They are all directed towards this mechanism of replacing a missing copy of a gene. We have built on the back of that strategy a pipeline of four drug development candidates that are in the pipeline to date. We are going to go through each one of those in sequence to give you an an update on exactly where we have got to, and then a deeper dive in relation to what we see as coming for each one of those drug programs over the course of the next 24 months.
We are going to use that to do something a little bit different today to what we have done throughout the investor updates over the course of the year. We're going to turn our mind beyond just the first iteration of the drug candidate to the additional investments that PYC is making to further improve the drug candidates within the pipeline. Here we're going to be looking at the second and third generation or iteration of these drug candidates, and guiding you through how the readouts that we will generate in the course of those additional investments in the enabling technologies is going to shape the company's medium to longer term future. That's where we will be progressing through, and as I mentioned before, we'll open up for Q&A at the end of the presentation.
As Peter mentioned, it's a very exciting time for PYC, and the company is extremely well-positioned. We have a substantial undertaking with respect to maturing three of these drug development programs into late-stage or registrational studies over the course of the next 24 months, as well as bringing a fourth drug development program into clinical development. The scale of the undertaking here is very ambitious, and as Peter has pointed out before, we have not demonstrated yet that we are capable of executing late-stage or registrational studies. We have a lot of growing to do as an organization as we build out the capabilities and infrastructure required to execute those studies. The critical data that is going to inform the success of the company going forward will come from what we call the clinical proof of concept readouts. The human efficacy data, in particular from the ongoing phase I/II studies.
Really what we're looking for there, both from a patient standpoint but also for the derivative commercial benefit, we're trying to understand what is the likelihood that this drug is going to make a meaningful impact in the lives of those patients. It's looking at the safety tolerability profile first, but secondly, the efficacy profile. We are in a relatively privileged position as a biotechnology company, as Peter pointed out, with respect to our balance sheet. We are well-resourced, and so we can run larger phase I/II studies and invest further in giving fidelity of the signal on the probability of technical success because we can enroll more patients, run the trials for longer, as a consequence of that balance sheet strength.
You are going to enter, from next year, a very data-rich window as we roll through some quite sizable phase I/II studies in each of these indications. In addition, there are platform and discovery programs going on where we look to extend the strategy of the company into other indications and possibly into additional target tissues. We're not going to speak about those today because from the company standpoint, we don't get a lot of certainty in relation to whether our efforts in this regard have yielded a fruitful outcome until 18 months after the provisional patent is filed, when we can see in the public domain who else has been working on those candidates within that timeframe, and whether we have in fact managed to capture the relevant prior art date that gives us conviction that we have secured the intellectual property associated with those candidates.
That work is ongoing, but it will be a topic of a future discussion when we have more certainty that we have a development candidate. There's a lot of excitement in relation to the company's polycystic kidney disease drug candidate. I've just got back from a trip to the U.S. where we met with a lot of investors. We also presented at the American Society of Nephrology Kidney Week and had the opportunity to engage with a large number of the renal physicians who we would like to enroll in that phase II/III study that you see on the right-hand side here. We've received a lot of feedback in relation to the program, where it's at, and what those stakeholders are looking for over the course of the next 12 months. I'll endeavor to share that with you as we go forward.
You can see here, we are in the part C and D multiple ascending dose study. We're in a repeat dose study in patients today, and the idea here is that this study, part C and D combined, gives us an insight into patients who are on drug for a window of 24 months continuously. It's the dimension that I spoke about previously about being able to invest in getting as close as possible the mirror to the registrational study that is going to follow. Here, we know that the development pathway in a registrational study is a 12-month primary readout on the volume of the kidney with a 24-month confirmatory endpoint on the function of the kidney. What we are doing is we are taking that study, which is likely to be conducted in several hundred patients.
We are going to enroll initially 24 patients, but we will expand that in to 50, 60, 70 patients through the course of next year to give a very rich insight in relation to what is going to unfold in the registrational study that follows. Where have we got to there? We are in the process of enrolling those first two patient cohorts of the two different doses that we've taken into clinical development. We presented the first data from the single ascending dose study in patients at the ASN conference. It was very interesting to hear the feedback from the clinicians there. There's less interest in the total kidney volume endpoint at this point in time. I think there's less confidence in early movement in relation to that endpoint. There's a lot more interest in the urinary PC1 biomarker.
For those who are new to the story, this drug is designed to go to the kidney and increase the expression of the PKD1 gene, which encodes the PC1 protein. And the PC1 protein is ultimately excreted by the kidneys into the urine. We can measure changes in gene expression within the urine of patients, which should be giving us a very good signal as to the level of gene expression within the kidney. It's a very good biomarker here, and I think the field as a whole take a lot of confidence, conviction from the movement that we've seen to date. The great excitement here is the magnitude of the upregulation, the 45% that we've seen after a single dose in the first seven patients who've been able to provide those samples is more than what we have seen for any other drug candidate.
That holds a great degree of promise. We know from the study run by Regulus Therapeutics of the farabursen molecule that we saw a 30%-40% upregulation after seven doses of the drug candidate in a repeat dose setting. There is a big opportunity for PYC now to show in the context of moving beyond the single dose studies into the repeat dose studies, the extent to which we can see upregulation of target gene in the kidney on the premise that the closer we can get that expression back to a 100% increase or a twofold upregulation takes us back to wild type expression levels and fully compensates for the haploinsufficiency.
There is now an enormous focus within the company in relation to building out the dataset from the N of seven patients in the SAD to an N of 20 patients with a preponderance for patients who are in the MAD, the repeat dose study, knowing that the inferred concentration of drug in the kidney will keep rising until the third dose of the drug candidate has been given. An enormous amount of interest and excitement there. At the plenary session at the end of the ASN conference, they gave an overview of the PKD field as a whole. They focused down the interest to three drug candidates, the disease modifying drug candidates in clinical development. The first discussion was of the Vertex molecule, the corrector, and I think there is a lot of enthusiasm for where that drug is heading.
I think the deficiency or the shortcoming there is it will only address about 9% of the patient population. You need to have a very specific type of mutation in order to enroll in that study and benefit from that drug's mechanism of action. That is seen more as a complement than a competitor to the other two disease modifying drug candidates, those being farabursen, acquired by Novartis, and pending that transition to the phase II/III study that now looks likely to occur next year, and PYC-003. The discussion here is if we can get conviction that we can see PC1 protein increasing in the kidneys, the bet that you are then taking is that is going to have a profound impact in the kidneys of those patients from an anatomical and later a functional standpoint.
From everything that we know about polycystic kidney disease and the preclinical models of that disease, re-expressing the missing protein has the potential not just to stop progression of the disease, but potentially even reverse it in some cases as well. A very exciting window for PYC. In the first half of next year, you should be looking for that urinary PC1 data, as Peter spoke about earlier. The idea would then be that we transition, subject to confirmation, to a U.S. listing, and the data that comes towards the end of the year, the proof of concept data on the registrational endpoint, total kidney volume, and perhaps some early insights on eGFR is made public in the second half of the year. 2027 really is the transformational year for the polycystic kidney disease program.
I'll pause there in case there are any questions or comments in relation to the core program itself.
Rohan, I was just wondering whether or not you think you'll have 20 patients' data available for the JP Morgan conference early next year?
Yes, I think that's certainly what we're aiming for. It is somewhat variable just with respect to the quality control processes on the samples of urine that are sent through to us, making sure they're within the linear range of the assay, but I think it's of the order of an N of 20 that we'll be looking for. Some of those will be patients. The other dimension is the repeat dosing that we'd like to look at, so an N of 20 in relation to the single dose, probably half that number for a second dose, and half that number again for a third dose. So it'll be a reasonably meaningful dataset, I think, by the time that that conference rolls around. Other questions? Good.
I think probably the other piece of feedback that is relevant to shareholders in relation to the investors on the U.S. circuit is the appreciation of the size of that study. So whilst we're predicating the initial assessment on the first 24 patients through, and we expect to have 12-month data for those patients by Q4 next year, we will continue to enroll that study, 50, 60, 70 patients. And in that, we will get a richness to that dataset. It's an open-label study, so over the course of the next 24 months, you're going to see urinary PC1, total kidney volume, eGFR outcomes from a very large number of patients that ultimately is likely to overlap the enrollment in the phase III. So it's a very data-rich window for investors. You're not exposed to binary risk.
You're going to see the evolution of the data come to hand over time. Where we're heading with respect to the program is a transition to a potential different route of administration. We'd like to move from the once every six-week IV infusion that we have for the first generation of the molecule, potentially to a subcutaneous route of administration for the second generation of the molecule. Some very encouraging early work has been done there in rodents. We now need to progress to non-human primate studies or monkeys to ensure that we can recapitulate that data in the context of the larger animal species, and you should expect to be hearing about that next year as well.
In the context of seeing robust target engagement and potentially an alternative mechanism of action, if we know that we can solve the delivery challenge for precision medicine to the renal tubular epithelial cells, that will encourage us to look at other diseases that are causing in that cell type, because I think we have a genuine competitive differentiation there with respect to the ability to reach cells that other technologies cannot. A big opportunity for the organization to expand further within kidney disease. Just synthesizing those points, if we look first to the right-hand side of the page and the immediate objectives, clinical proof of mechanism, showing that the drug is having the intended effect and increasing target gene expression within the kidney, and later clinical proof of concept towards the second half of next year.
We've got a big body of work to do to finalize that registrational study design. At this time next year, we'll be in the final throes of gearing up for execution of that phase III study. That's Peter's point about the organizational development. We need to have an extensive series of interactions with the regulator to understand exactly what their expectations are for that study, and we'll be providing, in addition to that, those longer-term readouts from the open-label extension of the phase I-B study. We spoke about in terms of the direction, strategic direction that the company is heading, the route of administration optimization, potentially additional complementary mechanisms to see whether we can further upregulate the PC1 expression as well.
From there, we will be looking to those other disease indications where we are marrying that clinical safety profile that we've seen to date with the evidence of target engagement, with the concept of identifying other diseases that are occurring in the same cell type so that we can leverage that clinical profile and that delivery technology. All good? Any questions online? Yeah, I'm happy to take them now.
The PKD-relevant ones. The single-dose data, urinary PC1 peaking at day 14 and fading by day 28 without preempting results. Is the repeat dose regimen tracking to hold PC1 up between doses?
Yeah, as I mentioned before, what we're looking to see here is how we track from a urinary protein upregulation standpoint through the course of the first three doses. The reason for that is because both the Cmax and the C trough is rising in the kidney, based on the modeling from the non-human primates for those three doses. So it's too early to make the call as to whether day 14 is the peak, and we would need to shorten the dosing interval there. I think the great thing from the company standpoint is we're open in both parameters. We have the ability to shorten the dosing interval if we need to, because we have run the GLP tox studies at a decreased frequency, sorry, an increased frequency or decreased dose interval.
Because we haven't hit any dose-limiting toxicity, if we needed to further escalate the dose, we can.
Yep. Still on PKD, I think you've largely answered this. When should shareholders expect the next PKD data, repeat dose biomarker data early in 2027, and the first multi-dose kidney volume read in the third quarter? How confident are you in those dates?
I think we're in a very good position. I think fortunately, the company has an excellent clinical operations team, who, under the supervision of the program team, have done a terrific job at enrolling the phase I-B study there. We are very confident that we will be able to meet the projected timelines in relation to the first two cohorts of patients enrolled within that study. There is more uncertainty as you look to the 50, 60, 70 patients, but we obviously have a longer time period in which to recruit those patients going forward.
Yeah, and I think that largely answers some of the next questions, referring to whether the pace is fast enough, and if the PKD repeat dose cohorts are fully enrolled, and if not, when will they be? Yeah, and whether they're enrolled to reach 12 months of dosing within calendar year 2027.
Yeah, so the guidance that we gave was to ensure that we had full recruitment of C1 and C2 within the fourth quarter of 2026, and we remain on track for delivery of that milestone. Yeah, we're very comfortable in relation to the execution and where we've got to there.
Few more PKD ones, and then I think NASDAQ ones, which we can probably maybe come back to later.
At the end.
How do you see PYC-003 positioned against Novartis's farabursen, and has their progress changed your plans or urgency? I know you mentioned about the comparison to the UPC1 data, but
Yeah, look, very helpful again to engage with the renal physicians. We had an ingoing view from our standpoint as to where we stood in the competitive landscape there. It is clear that it comes down to two dimensions: safety, tolerability, and the efficacy side of things. I think too early for us to call on the efficacy side of things beyond the urinary biomarker and what we have seen from the single-dose study. We do not have data from farabursen to be able to compare to, so I think you are having to wait there for the repeat dose data. Based on the preclinical differentiation, it is the biodistribution in the kidney that I think is key here, right? We have 10 times as much drug in kidney at like-for-like dosing with farabursen. That affords a much more broad, even, and deep distribution throughout the kidney.
We know this is an intracellular protein deficiency. Even though there is a strong paracrine effect within the kidney, sharing of the protein amongst the cells locally, the more cells that you are reaching in the kidney, the better the outcome is going to be. So the hope is that that manifests as urinary PC1 differentiation. In the meantime, what we have seen from a safety tolerability standpoint, there remain concerns with respect to the specificity of the microRNA-17 inhibition from farabursen. The microRNA that is being targeted by that drug is regulating hundreds of genes inside the cell, and there is only one of them that you are really wanting to change the expression of. PYC's molecule engages directly with the PKD1 transcript, so that is the differentiation there.
We know from the farabursen studies that there was a disturbance of the liver function in those patients, so there was some evidence of hepatotoxicity, ALT and AST elevations. We do not see that with 003 to date. The final dimension there is, you saw even in the confines of a 16-week repeat dose study with farabursen, multiple patients are dropping out of the study because of the injection site reactions. They do not like the wound breakdown associated with the negatively charged chemistry for oligonucleotide. I think we have an emerging safety tolerability differentiation. We would love to complement that next year with an efficacy differentiation as well.
One more aspect of differentiation. Do you think you will beat Novartis Regulus to market, or still behind?
That is a very interesting question, and it is too early to answer it. It is going to be dependent upon the effect size that we observe in the phase I-B study. The magnitude of the effect dictates the biostatistics calculation required to achieve statistical significance, and then overpower to the safety margin that we are comfortable with in relation to realization of those endpoints. We need to go and have a conversation with the regulator in relation to exactly what their expectations are, and then marry that with the interpretation of the phase I-B data.
That is exactly the point that Pete is making around the sophistication of our organization, standing up the steering committee, inviting those global KOLs to coordinate through our Chief Medical Officer, and the other support staff into that program, take on board the patient advocacy group progress that has been made here, engage with the payers in relation to the reimbursement profile of the drug candidate, and also accommodate the dynamic variable. We have seen at the Kidney Week presentation, patients who are on the GLP-1 drugs have a reduction in total kidney volume. So, we need to accommodate for rolling variables like that in the design of the study. We have a lot of work to do and a very narrow window within which to execute that through the course of the next 12 months. Too early to say is the short answer on sizing.
The big advantage that we have there is we will be basing the phase III design on 12 months worth of data. I think the challenge for Novartis now is predicating their faricimab registrational study on the 16-week data that was available from their MAD patients discontinued at the end of that timeframe. It is, I think, a significant benefit that PYC is afforded that we do not see for Novartis there. That is polycystic kidney disease. I think a very exciting time for the program as a whole, and we are looking forward to updating you in the very near term, both in relation to trial recruitment progress, but I think very importantly, that proof of mechanism data early next year.
It is always an exciting time when you are on the cusp of launching first-in-human studies, particularly for a disease-modifying drug, particularly for a disease-modifying drug candidate that is the first drug to upregulate full wild-type protein in the domain of the cell in which it is required to restore functionality. On the back of a very strong preclinical data pack that is a great credit to Jania and the team, we anticipate progressing the Phelan-McDermid syndrome program for Sierra and patients like her into human studies next year. The stage of development that we are at today is the GLP toxicology studies. We have completed our single-dose studies and have nearly completed the repeat-dose studies. We thought we would be submitting an IND in the first half of next year, and enrolling patients in the second half of the year.
In engaging with the FDA through the pre-IND study, the premise of that assumption, it turns out that the FDA have a different view in relation to the way they would like that clinical study to be run. They do not want to have a single-dose study followed by a repeat-dose study. They want us to progress directly into a repeat-dose study. Subject to confirmation, I think it is likely that we will accede to the recommendation of the regulator there. The IND will likely be in the second half of the year, because what that means is we have to complete our chronic tox studies to ensure that patients can roll directly over from the repeat-dose study into an open-label extension, that there is no gap in dosing there.
That will be the path, the development pathway that we follow there, and I think there is a huge amount of excitement building in relation to this drug candidate. A lot of the U.S. investor feedback is demonstrating the increased understanding of the potential for patient impact and the derivative commercial benefit in another very large indication, beyond the polycystic kidney disease program. It is very nice to hear back from those investors that there are more programs of interest for them within the pipeline. The other open body of work that we are expecting initial results from before the end of the year is the final piece of the preclinical data pack that is currently missing, the in vivo therapeutic model of Phelan-McDermid syndrome, or the rat model, where we have the haploinsufficiency. The rats are manifesting the deficiency of the gene.
We are looking to see whether or not we can restore SHANK3 expression back to or towards those wild-type levels. That data should be available before the end of the year, and then we will have functional outcomes from that model next year, and that really rounds out the data pack for Phelan-McDermid syndrome. RNA therapies to turn gene expression up are an increasingly competitive domain within the industry. If you look at what is happening in some of the other indications here, where other companies are progressing these assets for patients with different genetic mutations, and in particular, Stoke Therapeutics and their Dravet syndrome candidate, you can see other companies looking to create an incremental benefit with a second-generation molecule that is slightly earlier in clinical development. We know here that the one drawback of the approach that we have taken in Phelan-McDermid syndrome is the route of administration.
This is a direct injection into the lower spine to access the fluid that bathes the brain, because it is very difficult to get an RNA drug across the blood-brain barrier via a systemic route of administration. It is fine, it is perfectly acceptable to patients. There are multiple drugs on market already that are a substantial success in relation to both patient impact and the commercial benefit that follows from that with an intrathecal route of administration. Ideally, you do not want to be dosing the patients once every three to four months. That is a substantial burden for a patient who has a neurodevelopmental disorder and is primarily in the pediatric indication, although we expect adults to be treated as well.
What we would like to see here is an extension of the dosing interval. Again, there is some very exciting work that we expect to be talking to you about in the fullness of time next year, once that has matured in relation to a substantial increase in that dosing interval. We have then followed the progress of the field. Some of you who will be watching Arrowhead Pharmaceuticals and their ability to administer subcutaneously an RNA therapeutic that is capable of knocking down gene expression in the brain of healthy volunteers, by in the order of 70%, and achieving a very broad, even, and deep distribution through the non-human primate brain. We will be looking to a systemic route of administration for the third generation of that drug candidate that follows.
If we are successful in that domain, that will open up a platform for us for pursuing other central nervous system disorders. We have some early candidates there that we are interested in adding to the pipeline as well. Any questions on PMS?
One online. They were looking to understand the regulatory pathway on PMS. They used the word unfortunately, but it sounded like they are encouraging you to jump forward to the phase II/III. What is the unfortunate part?
Maybe I misspoke in relation to the words. Unfortunate with respect to the timing of the IND submission, so I was just giving an explanation as to why that has moved from previous guidance in the first half when we thought we were going into the SAD, into the MAD, going directly into the MAD. I can very much understand the regulator's view here. The view is that they would like to have patients have the prospect of benefiting from the drug candidate. I think that is a very salient point and one that we appreciate, and for that reason, I think we will accede to the recommendation of the regulator there. All happy on PMS?
In ADOA, we have spoken previously about the really beautiful additional pieces of non-clinical data that came earlier this year when a non-human primate or monkey was dosed with the human equivalent of the mid-dose from the ongoing clinical studies, and we saw a two-fold increase in target gene expression in the retina four months after a single dose of the drug candidate. As far as translational data goes, that is a really beautiful piece of information for us. What we did not do there was follow out the time course beyond four months. So much like with Phelan-McDermid syndrome, the open question here is how frequently do we need to dose patients? The current clinical protocol suggests once every eight or 12 weeks, and we are the beneficiaries here of a remarkably clean safety tolerability profile, so that is acceptable.
Again, it would be ideal if we can further extend that dose interval. We will go back and rerun those non-human primate studies next year, looking at 6, 9, and 12-month time points to see whether we can maintain that target gene expression at those levels for longer, and consequently use that to inform the design of the clinical studies. The data in the clinic is emerging very nicely. You have seen multiple scientific conference updates through the course of the year where the biomarker of retinal stress in patients who have received the drug candidate is significantly improved in the context of the treated eye. We do not see that in the fellow untreated eye.
Patients are having the drug candidate in just one eye, and that is correlating very nicely with the extent of the visual acuity improvements seen in those patients, which is ultimately going to be the registrational endpoint here. What we need to see now is just a more mature data set with respect to design of that registrational study. We want to see patients on drug for 12 to 24 months before we have conviction that we can design that registrational trial with a high propensity of yielding the outcome that we're looking for. That clinical proof of concept readout is anticipated in the second half of next year. There's also an additional body of work that we're not going to go into today, but just as a reminder that this is ongoing.
Most of our drugs are only suitable for patients with the specific genetic indication that we're pursuing. This one is unique in the sense that it is upregulating a mitochondrial protein, and the mitochondria is the energy unit of the cell. There are other indications, particularly other blinding eye diseases affecting the same cell type, that we are interested in using the safety profile established in the ADOA patient population and some non-clinical data to suggest benefit in those other indications, combining those two together and going directly into a phase II, probably investigator-led study to evaluate the clinical utility of that asset. Any questions on ADOA? Very similar journey to the PKD program, an accelerated timeframe for transition into a registrational study.
The TPP there, the target product profile, largely refers to the outcome of that non-human primate study that we spoke about, and then the pipeline and a program potential demonstrating the applicability of the drug candidate in those other indications. All happy on PMS? Sorry, ADOA. The final program, in retinitis pigmentosa type 11 is in a very similar stage of development to the ADOA program. It's in ongoing phase I/II studies, and we are waiting here for the data to mature. I think the one drawback to this program is the asymmetry between the extent of the improvement that we're seeing in the visual acuity in the patients who are receiving the drug with the regulator's expectations of a registrational outcome.
Those five, six, seven letters of visual acuity improvement that patients who've been on the drug are seeing, is not linking currently to the 15 letters of improvement that the FDA would like to see. We do have an issue in relation to either keeping those patients on drug for a longer period of time, or changing the nature of the endpoint that we select, or going back to the FDA and seeking additional registrational flexibility with respect to what is the bar for registration here. I think being very transparent with everybody, it's probably the one weak point at the minute in the development pipeline, is just trying to reconcile the gap there. It's a very important drug candidate despite the fact that it's for a much smaller patient population than the other indications in the pipeline.
The reason that this is so important is because the retinitis pigmentosa type 11 patient community don't have any other drug candidates available for them. The standard of care today is genetic counseling, and there are no other drug candidates in clinical development. We need to have a conversation with the regulator in relation to clinical meaningfulness, because many of you have seen the patient-reported outcomes from patients who are enrolled in that study and the very significant impact that it is having in their lives. That's the pipeline. We will open up now more broadly to questions on other dimensions of company's operations and ambitions.
One online, just a general question. Can you explain across all programs what level of access can be gained to real-time data by interested parties, such as offshore investors or pharma looking to partner?
Yeah, the majority of the ongoing phase I/II studies, all of them, in fact, are open label. Non-placebo-controlled studies, which means we get access to the data as it comes to hand in real time. We do maintain, curate and maintain data rooms. As the clinical data matures to certain thresholds, we will update those data rooms and engage in conversations with industry counterparts to ensure that we are bringing them on the journey. It's very helpful to learn from those big pharma conversations exactly what they're looking for, and it also helps us to calibrate, are there any additional pieces of information or thoughts in relation to study design or other elements of the program, that we have not countenanced.
I think everybody is aware, we've been engaged in ongoing dialogue with the pharmaceutical industry, throughout the pipeline, increasingly on the polycystic kidney disease asset, an emerging interest in PMS as well. Probably lesser interest on the part of the big pharma in relation to the ophthalmology assets, although ADOA is starting to change there as well. As that data pack matures and access to the individual patient level data that sits underneath the headline information that's been presented scientifically, you can see an appetite building in relation to counterpart interest there as well.
If we're waiting for anyone else in the room, a group of questions just associated with NASDAQ listing, so looking for insights on the thinking, what timelines, whether it might be expected to include a capital raise, and whether you'd wait for the kidney volume data to feed into that timeline.
I think in relation to the timelines, Peter outlined in his address that I think guidance would be towards the second half of next year. I think the idea there would be to establish the proof of mechanism data in the polycystic kidney disease program. Potentially some PKD, sorry, total kidney volume data at the time of the listing, maybe that comes afterwards. I think that one's open for discussion and is pending on how the data there evolves. I think given the focus of the community as a whole on the urinary biomarker and target gene modulation in the kidney, it may not be needed. With respect to whether we'd raise money, that really comes down to a question of valuation and how much recognition and appreciation of that data is manifest in the Australian market capitalization at the time that we're looking to list.
As Peter spoke about previously, we're funded into calendar year 2030, so there is no obligation to raise. Whether or not it would be a good thing to raise will largely depend on where the share price is at the time.
One other one there. The Chair said the board will consider how long to keep the dual structure. Is the long-term intention to remain ASX listed?
You want to comment on that one, Peter?
No, just another UPC, PC1 data.
Do you want to switch it round to UPC1 and then I'll hand back to Peter and-
Sure, yeah. If the urinary PC1 data leads you to shorten the dosing interval or raise the dose, does the 12-month kidney volume data from the first 24 patients in Q4 2027 still stand as proof of concept, or does the clock restart on the new regimen?
We'd have to make the decision at the time based on what the data was demonstrating at that point. Remember, and I think it's a big part of the advantage in relation to the continuous recruitment or over-recruitment of that study, is we have the potential to change the clinical protocol for the later applicants. That would then mean that you don't have the full 12 months worth of dataset on TKV, but that may not be necessary, again, because it's an open-label study and we expect the six, nine, 12, six, nine-month data to be informative of where we land on the 12-month side. It's subject to what we see. It's too difficult to speculate on what might be there.
I think the strength here is a lot of flexibility with respect to the parameters and the over-enrollment of patients enabling us to move with the dynamic nature of the data in the event that we do decide that it requires refinement. Yeah. All right, thank you. I'll hand back to you, Peter.
We had the lights back on. Some of us have older eyes than the younger ones in the room. Look, thanks, Rohan. Thanks for that update, and thanks, everybody, for your questions. Look, just a couple of things to circle back. I mentioned during my presentation earlier on that we're on a journey, and it's a journey that PYC hasn't been on before. I do want to recognize, though, that there are some things that we're doing and we're doing very, very well that shareholders should have confidence in. If you think about what we really need to execute on to get these programs to the maturity that we all aspire to, firstly, we've got to get patients enrolled in the programs. Of course, that enrollment needs to increase substantially during the back end of 2027 in particular.
I can tell you today, though, PYC is doing this as well as anybody. So congratulations to the team. This is not easy, as Rohan mentioned, to get patients to volunteer for these programs, to take on board an unknown drug, and to come with us on the journey. But the team's done an exceptional job at that, and I've had feedback from one of our larger investors in the U.S. that PYC gets an A for that and what we've been doing. So we can get some confidence in the processes and the systems we have in place for the enrollment of patients into the studies. But of course, the disclaimer of all of these things is past performance is no indicator of future performance. Of course, we need to substantially increase the rate of enrollments into the programs. But we recognize that.
The good thing is we're coming off a strong foundation or a strong base in that, but it's a lot of work. On the FDA side, Rohan mentioned there's a lot of discussions with the FDA that will need to occur during 2027. Rohan's also built out his team in the U.S., so we are developing and recruiting that expertise in the U.S. We recognized that early, and we recognize that we need to get the right people on board. We can only do that if those people can see a pathway to completion of the program.
So thank you again to shareholders for the support you've given us through the capital raise earlier in the year, and we can actually go out to those people, and they can see that our shareholders have supported us, they're supporting all of the programs, and those programs are funded out through the end of next year. Of course, the important thing is the results of the programs, and of course, Rohan's just indicated we've got some positive results so far, but we're very pragmatic about what we're dealing with here and the risks associated with it. But nonetheless, the programs are all indicating positive results. Then just finally, thank you for your support on the finance. There's kind of an old rule in business, often, particularly in smaller companies, you can't raise money and execute flawlessly at the same time.
You run into a management bandwidth issue on trying to do both. We now clearly have raised the money that we need to continue to advance our programs and move them forward so we can focus on that flawless execution with confidence. So thank you for that. Now, on the questions with respect to NASDAQ listing, we're in the process of engaging advisors for that in the U.S. and here in Australia to make sure that we get the right balance between the needs and desires of our Australian shareholders and then, of course, being able to attract U.S. shareholders onto the register. The key there is making sure that whatever we do on a listing, that we go into the U.S. with positive momentum and to be very well-known to the market from day one.
As Rohan mentioned, it's about creating that desire to own PYC shares and making sure that the market knows us. We can't just simply turn up and say, "Here we are. Look at us." That's just simply not going to work. We know we need to do a lot of hard work to make sure that the U.S. market knows us, understands us, and wants to be part of the journey that we're on, and that requires a lot of work. So it's not just about, as we've talked about, Sarbanes-Oxley compliance and a whole bunch of other things. It's about creating demand from a new investor base and building out that investor base, understanding the current investors we have in the U.S. will be long-term with us, and they're not trading in and out of the stock.
So by definition, they are not providing liquidity in the stock on a day-to-day basis, and we need to look at how we provide that liquidity so that we can have that U.S. base. If we go to a NASDAQ listing, start to drive demand in the stock and drive up that stock price, because at the moment, of course, it is being driven primarily by Australian investors. With respect to listing on the ASX and how long that continues and whatever it looks like, all I can say today is we recognize that as a key success factor in anything we do. I am not going to give any indications today as to what that may look like or how long that will stay in place and so forth. Let us listen to the advisors, take that on board, and consider it.
What I can assure you, though, is you are first and foremost in our minds as we go through that, and we will try and strike the right balance on whatever that looks like. It is just way too early for us to be talking about what that structure might look like, because we just have not received the advice and been able to debate it that we need to. So finally, now what we will do is just have a look at the results. The poll has been finalized, so thank you, everybody. Thanks for your questions. Thanks for your votes. I can tell you that all of the resolutions have passed, so thank you for that. We do not have the numbers up, but we will post them up on the ASX here soon, so you will be able to see that.
With that then, that concludes the formal business of the annual general meeting. Thanks for your attendance, your questions, and participation. I now declare the meeting closed. We will be around here for a little while, and we will answer any questions or anything that you may have if you want to meet some of the leadership team or the directors. So thanks very much for coming along today.